Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001490857 | SCV001695430 | likely benign | EGFR-related lung cancer | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257378 | SCV002537347 | likely benign | Hereditary cancer-predisposing syndrome | 2020-10-09 | criteria provided, single submitter | curation | |
KCCC/NGS Laboratory, |
RCV003315566 | SCV004017424 | likely benign | Lung cancer | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003421950 | SCV004162148 | likely benign | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | EGFR: BP4, BP7 |
Ambry Genetics | RCV002257378 | SCV005023535 | likely benign | Hereditary cancer-predisposing syndrome | 2023-12-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV003421950 | SCV005227381 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Laboratory for Molecular Medicine, |
RCV000038426 | SCV000062098 | likely benign | not specified | 2008-03-01 | no assertion criteria provided | clinical testing |